Literature DB >> 26869051

Estimating effectiveness in HIV prevention trials with a Bayesian hierarchical compound Poisson frailty model.

Rebecca Yates Coley1, Elizabeth R Brown1,2.   

Abstract

Inconsistent results in recent HIV prevention trials of pre-exposure prophylactic interventions may be due to heterogeneity in risk among study participants. Intervention effectiveness is most commonly estimated with the Cox model, which compares event times between populations. When heterogeneity is present, this population-level measure underestimates intervention effectiveness for individuals who are at risk. We propose a likelihood-based Bayesian hierarchical model that estimates the individual-level effectiveness of candidate interventions by accounting for heterogeneity in risk with a compound Poisson-distributed frailty term. This model reflects the mechanisms of HIV risk and allows that some participants are not exposed to HIV and, therefore, have no risk of seroconversion during the study. We assess model performance via simulation and apply the model to data from an HIV prevention trial.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Bayesian analysis; data augmentation; heterogeneity; latent variable; survival analyisis

Mesh:

Year:  2016        PMID: 26869051      PMCID: PMC5039019          DOI: 10.1002/sim.6884

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  31 in total

1.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

2.  A Bayesian hierarchical modeling approach for studying the factors affecting the stage at diagnosis of prostate cancer.

Authors:  Huafeng Zhou; Andrew B Lawson; James R Hebert; Elizabeth H Slate; Elizabeth G Hill
Journal:  Stat Med       Date:  2008-04-30       Impact factor: 2.373

Review 3.  Frailty models for survival data.

Authors:  P Hougaard
Journal:  Lifetime Data Anal       Date:  1995       Impact factor: 1.588

4.  Does Cox analysis of a randomized survival study yield a causal treatment effect?

Authors:  Odd O Aalen; Richard J Cook; Kjetil Røysland
Journal:  Lifetime Data Anal       Date:  2015-06-24       Impact factor: 1.588

5.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

7.  The hazards of hazard ratios.

Authors:  Miguel A Hernán
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

8.  PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

Authors:  Sheena McCormack; Gita Ramjee; Anatoli Kamali; Helen Rees; Angela M Crook; Mitzy Gafos; Ute Jentsch; Robert Pool; Maureen Chisembele; Saidi Kapiga; Richard Mutemwa; Andrew Vallely; Thesla Palanee; Yuki Sookrajh; Charles J Lacey; Janet Darbyshire; Heiner Grosskurth; Albert Profy; Andrew Nunn; Richard Hayes; Jonathan Weber
Journal:  Lancet       Date:  2010-09-17       Impact factor: 79.321

9.  Multistage models and primary prevention of cancer.

Authors:  N E Day; C C Brown
Journal:  J Natl Cancer Inst       Date:  1980-04       Impact factor: 13.506

10.  Frailty modelling of testicular cancer incidence using Scandinavian data.

Authors:  Tron A Moger; Odd O Aalen; Tarje O Halvorsen; Hans H Storm; Steinar Tretli
Journal:  Biostatistics       Date:  2004-01       Impact factor: 5.899

View more
  3 in total

1.  Compound Poisson frailty model with a gamma process prior for the baseline hazard: accounting for a cured fraction.

Authors:  Maryam Rahmati; Parisa Rezanejad Asl; Javad Mikaeli; Hojjat Zeraati; Aliakbar Rasekhi
Journal:  J Appl Stat       Date:  2021-07-05       Impact factor: 1.416

2.  Adaptive non-inferiority margins under observable non-constancy.

Authors:  Brett Hanscom; James P Hughes; Brian D Williamson; Deborah Donnell
Journal:  Stat Methods Med Res       Date:  2018-10-08       Impact factor: 3.021

3.  Joint modeling of time-varying HIV exposure and infection for estimation of per-act efficacy in HIV prevention trials.

Authors:  Elizabeth R Brown; Clara P Dominguez Islas; Jingyang Zhang
Journal:  Stat Commun Infect Dis       Date:  2020-09-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.